Recent advances in leukotriene B4 receptor antagonist research

Expert Opinion on Therapeutic Patents

Volumn 6, Issue 1, 1996, Pages 21-28

  Fretland, D J ^a   Penning, T D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; BENZAMIDINE DERIVATIVE; BERBAMINE DERIVATIVE; CEPHARANOLINE DERIVATIVE; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LY 292728; MOXILUBANT MALEATE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RO 25 4094; SB 201993; SB 209247; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; CELL FUNCTION; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MEDIATOR RELEASE; NONHUMAN; PATENT; PNEUMONIA; REVIEW; SKIN INFLAMMATION; TISSUE INJURY; ULCERATIVE COLITIS;

EID: 0030046948     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.6.1.21     Document Type: Review

References (0)